false 0001533998 0001533998 2024-12-18 2024-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): December 18, 2024

 

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware  001-37704  45-2973162
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

122 W 57th St, #33B
New York, New York 10019

(Address of Principal Executive Offices)

 

972- 4-770-6377

(Issuer’s telephone number)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which 
registered
Common Stock, par value $0.0001 per share   DRIO   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 18, 2024, DarioHealth Corp. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”). The final voting results of the 2024 Annual Meeting are set forth below. Stockholders voted on the following proposals:

 

Proposal No. 1 — Election of Directors.

 

The stockholders elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis):

 

Director Name   For   Against   Abstain   Broker Non-Votes
Hila Karah   15,939,360   127,477   35,224   6,671,020
                 
Dennis Matheis   15,823,755   243,082   35,224   6,671,020
                 
Dennis M. McGrath   15,864,338   201,911   35,812   6,671,020
                 
Erez Raphael   15,936,730   129,564   35,767   6,671,020
                 
Yoav Shaked   15,861,165   205,129   35,767   6,671,020
                 
Jon Kaplan   15,871,746   195,090   35,225   6,671,020
                 
Adam K. Stern   15,913,677   143,403   44,981   6,671,020

 

Proposal No. 2 — Ratification of Auditors.

 

The stockholders ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. The votes were as follows (including shares of preferred stock eligible to vote, on an as converted basis): 

 

For   Against   Abstain
22,649,674   106,250   17,517

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 18, 2024 DARIOHEALTH CORP.
   
  By: /s/ Zvi Ben David
    Name: Zvi Ben David
    Title: Chief Financial Officer, Treasurer and Secretary

 

 

 

v3.24.4
Cover
Dec. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 18, 2024
Entity File Number 001-37704
Entity Registrant Name DARIOHEALTH CORP.
Entity Central Index Key 0001533998
Entity Tax Identification Number 45-2973162
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 122 W 57th St
Entity Address, Address Line Two #33B
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10019
City Area Code 972
Local Phone Number 4-770-6377
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol DRIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

DarioHealth (NASDAQ:DRIO)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025 Plus de graphiques de la Bourse DarioHealth
DarioHealth (NASDAQ:DRIO)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025 Plus de graphiques de la Bourse DarioHealth